• Labcyte

  Participated · Series D · Jan 2013

  Labcyte is a Sunnyvale, California-based global biotechnology tools company that develops contact-free liquid handling systems enabling precise, pipette-free liquid transfers. Led by president and chief executive officer Mark Fischer-Colbrie, Labcyte's instruments are used across the pharmaceutical industry, diagnostic companies, genome centers, genomic service companies, biotechnology firms, contract research organizations, and academic institutions. Customers apply Labcyte's systems in drug discovery, genomics, proteomics, diagnostics, precision medicine, and imaging mass spectrometry. The company holds 55 U.S. patents and additional international patents. Labcyte received a $17M credit facility — a $10M senior secured term loan and a $7M line of credit — from Oxford Finance and Silicon Valley Bank. It intends to use the proceeds for research and development and to expand its worldwide business. Labcyte builds Echo® acoustic liquid-handling systems that use sound to transfer liquids without contact, eliminating pipettes and enabling precise, low-volume dispenses. Its platform combines acoustic dispensing with automation and software to miniaturize assays, reduce reagent use and improve data quality and reliability. Customers include pharmaceutical, biotechnology, diagnostic and contract research companies as well as academic institutions, with applications across genomics, proteomics, diagnostics, personalized medicine and imaging mass spectrometry. Labcyte holds 62 global patents and has additional filings supporting its technology. The company says the new funding will enable expansion of its product lines and accelerate growth of its established global customer base. Labcyte is headquartered in Sunnyvale, California and is privately held. Labcyte is a global life science instrumentation company based in Sunnyvale, CA. It provides instruments and global support to large and small-to-mid-size pharmaceutical companies, biotechnology firms, contract research organizations and academic institutions. Its technologies are applied across drug discovery, genomics, proteomics, diagnostics, imaging mass spectrometry and live cell transfer. Core product capabilities include proprietary acoustic liquid handling for arraying and workflows that prepare samples for MALDI mass spectrometry. The company is collaborating with Stanford's Canary Center to validate cancer biomarkers and to develop an advanced system for early cancer detection that integrates its acoustic liquid handling with MALDI preparation. The recent grant underscores its engagement with academic and government partners.

No current team members are available.